Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 28;20(1):21426.
doi: 10.7448/IAS.20.1.21426.

Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study

Anders Boyd  1 , Julie Bottero  2 , Patrick Miailhes  3 , Caroline Lascoux-Combe  4 , Hayette Rougier  5 , Pierre-Marie Girard  2   6 , Lawrence Serfaty  7 , Karine Lacombe  2   6
Affiliations

Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study

Anders Boyd et al. J Int AIDS Soc. .

Abstract

Introduction: Long-term tenofovir disoproxil fumarate (TDF) use has been associated with significant regression of liver fibrosis during hepatitis B virus (HBV) mono-infection, yet little is known during HIV-HBV coinfection. The aim of this study was to evaluate the evolution of liver fibrosis and its determinants in TDF-treated coinfected patients.

Methods: In this prospective cohort study, 167 HIV-HBV-infected patients initiating TDF-containing antiretroviral therapy were included. Fibrosis was assessed using the FibroTest® at baseline and every six to twelve months. Risk factors for fibrosis progression (F0-F1-F2 to F3-F4) and regression (F3-F4 to F0-F1-F2) were evaluated.

Results: At baseline, 134 (80.2%) patients had detectable HBV-DNA (median = 4.93 log10 IU/mL, IQR = 2.94-7.15) and 104 (62.3%) had hepatitis B "e" antigen-positive serology. Median follow-up was sixty months (IQR = 36-93). In the 47 (28.1%) patients with F3-F4 baseline fibrosis, 7/47 (14.9%) regressed to F0-F1-F2 at last follow-up visit. Fibrosis regression was significantly associated with higher CD4+ cell counts (P = 0.009) and lower fasting triglyceride levels (P = 0.007) at TDF-initiation. In the 120 (71.9%) patients with F0-F1-F2-baseline fibrosis, 20/120 (16.7%) progressed to F3-F4 at last follow-up visit. Fibrosis progression was associated with male gender (P = 0.01), older age (P = 0.001), from low/moderate HBV-endemic country (P = 0.007), lower nadir CD4+ cell count (P = 0.03), higher fasting glycaemia (P = 0.03) and anaemia (P = 0.004) at TDF-initiation. Control of HBV replication at end of follow-up was extensive (88.1%), while no HBV-related factors emerged as predictors of progression/regression. Incidence of severe liver-related events was low (n = 4, rate = 0.5/100 person-years).

Conclusion: Liver fibrosis levels are stable for most coinfected patients undergoing TDF, despite control of HBV replication. Nevertheless, a concerning amount of liver fibrosis progression did occur, which could be partly explained by metabolic abnormalities and past severe immunosuppression and requires further evaluation.

Keywords: hepatocellular carcinoma; immunosuppression; liver cirrhosis; liver fibrosis; noninvasive markers.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

Figures

Figure 1.
Figure 1.
Baseline liver fibrosis levels and HBV-related endpoints during tenofovir-containing antiretroviral therapy. Kaplan–Meier curves are used to depict time to HBV-related endpoints during tenofovir (TDF) containing ART, stratified on baseline none/mild/moderate liver fibrosis (F0–F1–F2) and fibrosis/cirrhosis (F3–F4). Time to undetectable HBV-DNA (<60 IU/mL) is represented in (a) among patients with detectable HBV-DNA at baseline. Time to HBeAg-seroclearance is represented in (b) among patients with HBeAg-positive serology at baseline.
Figure 2.
Figure 2.
Liver fibrosis evolution during tenofovir-containing antiretroviral therapy. In (a), the distribution of liver fibrosis levels is provided at each yearly interval during tenofovir (TDF) containing ART. The number of patients continuing follow-up at the end of each interval is provided below. In (b), individual trajectories of FibroTest® scores in function of their METAVIR fibrosis equivalents are provided in grey lines for patients with
See this image and copyright information in PMC

References

    1. Chen C-J, Yang H-I, Iloeje UH. REVEAL-HBV Study Group . Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009. May;49(5 Suppl):S72–12. - PubMed
    1. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013. August;58(2):505–13. - PMC - PubMed
    1. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014. February;59(2):434–42. - PubMed
    1. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013. February 9;381(9865):468–75. - PubMed
    1. Papatheodoridis GV, Chan HL-Y, Hansen BE, Janssen HLA, Lampertico P.. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015. April;62(4):956–67. - PubMed